Cellceutix Announces Ongoing Enrollment of Phase 2 Trial of Brilacidin for …

Cellceutix Announces Ongoing Enrollment of Phase 2 Trial of Brilacidin for …

Increasing patient access to the trial is important in the Company's efforts to discover an effective, safe therapy for oral mucositis and also to prove the anti-inflammatory properties of Brilacidin in a clinical setting. Laboratory studies have shown

(Visited 1 times, 1 visits today)
6
Like
Save

Comments

Comments are disabled for this post.